43.70
Schlusskurs vom Vortag:
$41.99
Offen:
$42.12
24-Stunden-Volumen:
3.02M
Relative Volume:
1.87
Marktkapitalisierung:
$5.67B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-507.65M
KGV:
-9.50
EPS:
-4.6
Netto-Cashflow:
$-616.24M
1W Leistung:
+2.44%
1M Leistung:
+36.56%
6M Leistung:
+55.85%
1J Leistung:
-60.84%
Vaxcyte Inc Stock (PCVX) Company Profile
Firmenname
Vaxcyte Inc
Sektor
Branche
Telefon
650-837-0111
Adresse
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Vergleichen Sie PCVX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PCVX
Vaxcyte Inc
|
43.70 | 5.45B | 0 | -507.65M | -616.24M | -4.60 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-09-12 | Eingeleitet | Goldman | Neutral |
2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-12-20 | Eingeleitet | Goldman | Buy |
2023-12-07 | Eingeleitet | Mizuho | Buy |
2023-04-18 | Eingeleitet | TD Cowen | Outperform |
2023-01-03 | Bestätigt | Needham | Buy |
2022-12-15 | Eingeleitet | Guggenheim | Buy |
2022-11-17 | Eingeleitet | BTIG Research | Buy |
2021-12-29 | Fortgesetzt | Jefferies | Buy |
2021-06-24 | Fortgesetzt | Jefferies | Buy |
2020-07-07 | Eingeleitet | BofA Securities | Buy |
2020-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-07-07 | Eingeleitet | Needham | Buy |
Alle ansehen
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Is Vaxcyte Inc. (5VA) stock cheap by valuation metricsQuarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
Will Vaxcyte Inc. see short term momentumMarket Activity Report & Daily Profit Maximizing Trade Tips - newser.com
Why Vaxcyte Inc. (5VA) stock is a strong analyst pickJuly 2025 Setups & AI Enhanced Trading Signals - newser.com
Thermo Fisher Scientific’s Valuation: Assessing the Impact of Its $1 Billion Vaxcyte Vaccine Manufacturing Deal - Yahoo Finance
Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX) - Yahoo Finance
What consensus target says about Vaxcyte Inc. (5VA) stockBuy Signal & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Vaxcyte Inc. (5VA) stock sustain dividend payouts2025 Retail Activity & Safe Entry Point Alerts - newser.com
111 Capital Takes Position in Vaxcyte, Inc. $PCVX - MarketBeat
PCVX Stock Price and Chart — NASDAQ:PCVX - TradingView
Will breakout in Vaxcyte Inc. lead to full recoveryExit Point & Reliable Price Breakout Alerts - newser.com
Is Vaxcyte Inc. (5VA) stock attractive post correctionJuly 2025 Market Mood & Risk Controlled Daily Trade Plans - newser.com
What candlestick patterns are forming on Vaxcyte Inc.2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com
Vaxcyte’s Strategic Moves: Impact on PCVX - StocksToTrade
BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Cuts Target Price to $134 - 富途牛牛
Why Vaxcyte Inc. stock is in analyst buy zoneWeekly Earnings Recap & Safe Entry Point Identification - newser.com
Earnings visualization tools for Vaxcyte Inc.Swing Trade & AI Driven Stock Price Forecasts - newser.com
A Look at Vaxcyte’s (PCVX) Valuation Following $1 Billion Thermo Fisher Manufacturing Deal - simplywall.st
Vaxcyte Inc.’s volatility index tracking explainedWeekly Trend Summary & High Return Trade Opportunity Guides - newser.com
Is Vaxcyte Inc. (5VA) stock a buy before earnings results2025 Historical Comparison & Growth Oriented Trade Recommendations - newser.com
Vaxcyte teams up with Thermo Fisher to ensure future vaccine production - MSN
What analysts say about Vaxcyte Inc 5VA stockMarket Rumors and News & Collaborate and Win Together - earlytimes.in
Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown - Sahm
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services - Sahm
Vaxcyte signs $1 billion manufacturing deal with Thermo Fisher By Investing.com - Investing.com Nigeria
Can Vaxcyte Inc. (5VA) stock sustain double digit ROEMarket Volume Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Vaxcyte, Inc. to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services - MarketScreener
What Does Wall Street Think About Vaxcyte (PCVX)? - MSN
Vaxcyte Signs 15-Year Agreement with Patheon - TipRanks
Vaxcyte to Establish Fill-Finish Manufacturing in North - GlobeNewswire
Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown - Benzinga
Vaxcyte to Expand Fill-Finish Manufacturing Capacity in US; Shares Up Pre-Bell - MarketScreener
Vaxcyte to Partner with Thermo Fisher to Increase Vaccine Production in U.S. - MarketScreener
Vaxcyte signs $1 billion manufacturing deal with Thermo Fisher - Investing.com
Vaxcyte and Thermo Fisher Scientific Sign Agreement to Enhance U.S. Manufacturing for Pneumococcal Vaccine Candidates - Quiver Quantitative
Finanzdaten der Vaxcyte Inc-Aktie (PCVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vaxcyte Inc-Aktie (PCVX) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):